[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563819":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":60,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Tianjin Huanhu Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TNK group",null,"The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg\u002Fkg, up to a maximum of 25 mg.",[13],"Other: Tenecteplase",{"label":15,"type":10,"description":16,"interventionNames":17},"rtPA group","The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg\u002Fkg, up to a maximum of 90 mg.",[18],"Other: Alteplase",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Tenecteplase","The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg\u002Fkg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Alteplase","The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg\u002Fkg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.",[15],[29],{"name":30,"affiliation":5,"role":31},"Jialing Wu, MD,PhD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Shoufeng Liu, MD","CONTACT","400-802-7885","shoufengliu2010@163.com",{"name":39,"role":35,"phone":36,"phoneExt":40,"email":41},"Yalin Guan, MD","0","guanyalinhh@126.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Tianjin","Tianjin Municipality","300350","China","CN",{"type":51,"coordinates":52},"Point",[53,54],117.17667,39.14222,{"lat":54,"lon":53},[57],{"name":58,"role":35,"phone":59,"phoneExt":10,"email":37},"shoufengliu Liu, MD","+86 13920017229",{"type":31,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jialing Wu","MD,PhD","100563819","a-real-world-study-of-tenecteplase-versus-alteplase-for-thrombolysis-in-patients-within-45-h-of-onset-of-ischemic-stroke-100563819",false,"NCT06621121","A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke","Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke : a Multicenter, Prospective, Observational, Real-world Study（TRANSIT）","TRANSIT","Inclusion Criteria:\n\n\\- 1. Symptoms of neurological deficit caused by ischemic stroke; 2. The time from onset to treatment ≤4.5 hours; The time of onset of symptoms was defined as the time of last seen normal.\n\n3\\. Age ≥18 years old; 4. Signed informed consent by patients or their legally authorized representative.\n\nExclusion Criteria:\n\n* 1\\. Any absolute contraindication to thrombolysis in the \\"Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023\\" 2.Allergy to TNK or alteplase 3.Participation in another clinical trial within the previous 3 months. 4.Other conditions deemed inappropriate for participation in this study.","ALL","18 Years",{"count":74,"type":75},6000,"ESTIMATED","OBSERVATIONAL","Stroke is the second leading cause of death worldwide, killing nearly 7 million people every year. Acute ischemic stroke is caused by focal cerebral hypoperfusion, usually due to embolism or atherosclerotic disease . Ischemic strokes account for 60-70% of all strokes worldwide and are severely debilitating, drawing considerable attention due to their high prevalence.The majority of studies comparing the efficacy and safety of teneplase and alteplase are predominantly randomized controlled trials with limited representation from real-world studies.The aim of this study is to compare the safety, efficacy and economic benefits of recombinant human TNK tissue plasminogen activator (tenecteplase, rhTNK-tPA, TNK) and recombinant tissue plasminogen activator (alteplase, rtPA) in clinical practice. This study aimed to establish a foundation for refining intravenous thrombolytic therapy tailored to various patient profiles and to guide clinicians in selecting the most suitable thrombolytic treatment options.",[79,21,25],"Stroke Acute",[81,82,83],"ischemic stroke","tenecteplase","alteplase","2024-10-26",{"date":86,"type":87},"2024-10-29","ACTUAL",{"date":84,"type":75},{"date":90,"type":75},"2026-10-01",{"name":5,"class":6},1]